Stem cells injected into brain to fight Parkinson's
NCT ID NCT05635409
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This first-in-human trial tests a stem cell therapy called STEM-PD for Parkinson's disease. Eight participants with moderate Parkinson's will have dopamine-producing cells transplanted into a brain region affected by the disease. The main goal is to check safety over 12 months, with follow-up for 3 years. Researchers also look for early signs that the treatment might improve symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
STEM-PD product (dopaminergic progenitor cells from human embryonic stem cells)
What this could lead to
If it works, this could point toward a treatment that repairs damaged brain cells in Parkinson's disease, potentially reducing the need for daily medication.
What could go wrong
This is a very early, small trial (8 people) focused on safety, not effectiveness. The stem cells may not survive or could cause side effects like brain swelling or abnormal growths.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cambridge University Hospitals NHS Foundation Trust
Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom
-
Region Skåne - Skåne University Hospital
Lund, 214 28, Sweden